Hologic gets win in ongoing dispute with SenoRx

The U.S. Court of Appeals for the Federal Circuit has reversed a ruling that invalidated Hologic's patent claims against a SenoRx device used for the treatment of breast cancers. The ruling comes more than two years after a California court decided in SenoRx's favor. 

Citing an incorrect claim construction, the appeals court reversed the lower court's ruling and remanded for further proceedings. "We are extremely pleased that the Court adopted our proffered claim construction and reinstated the validity of the claims of this pioneering patent in the area of breast brachytherapy," said Mark Casey, senior VP and general counsel.

Shares of Hologic were recently up 3.7 percent to $20.57, the Wall Street Journal reports. The stock has risen 22 percent in the past year.

SenoRx was acquired by CR Bard for $213 million last July, Reuters notes.

- see the Hologic release
- get more from Reuters
- check out the WSJ report

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.